Advertisement

Ibuprofen in children with cystic fibrosis: Pharmacokinetics and adverse effects

  • Michael W. Konstan
    Correspondence
    Reprint requests: Michael W. Konstan, MD, Pediatric Pulmonary Division, Rainbow Babies and Childrens Hospital, 2101 Adelbert Rd., Cleveland, OH 44106.
    Affiliations
    Department of Pediatrics Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio USA
    Search for articles by this author
  • Charles L. Hoppel
    Affiliations
    Department of Pediatrics Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio USA
    Search for articles by this author
  • Bao-ling Chai
    Affiliations
    Department of Pediatrics Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio USA
    Search for articles by this author
  • Pamela B. Davis
    Affiliations
    Department of Pediatrics Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio USA

    Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      Antiinflammatory therapy with ibuprofen has been proposed to retard the progression of lung disease in cystic fibrosis (CF). The pharmacokinetics and toxicity of ibuprofen were investigated in a randomized, double-blin, placebo-controlled, 3-month dose-escalation study in 19 children with CF, 6 to 12 years of age. The subjects received orally and twice daily 300 mg of drug during the first month, 400 mg in the second month, and 600 mg in the third month. Ibuprofen pharmacokinetics and evaluation for adverse effects were performed at the beginning and end of each month. The dose of ibuprofen was increased if peak plasma concentration (Cmax) was<50 μg/ml. To preserve the blind nature of the study, the dose in matched subjects taking placebo was also increased. The subjects randomly assigned to receive ibuprofen (n=13) completed 26 months of treatment; placebo subjects (n=5) completed 12 months. With dose escalation, Cmax and the area under the concentration-time curve from zero to infinity significantly increased (p<0.01). The pharmacokinetics of ibuprofen in 13 children with CF who received 13.4±4.1 mg/kg (mean ±SD) were compared with those in four healthy children who received a similar dose. Peak plasma concentration (48±17 μg/ml) was decreased by 27% (p=0.06), the area under the concentration-time curve (6.1±1.7 mg·min/ml) was decreased by 46% (p<0.001), apparent total clearance (2.3±0.6 ml/min ·kg−1) was increased by 77% (p<0.01), and apparent volume of distribution during terminal phase (291±91 ml/kg) was increased by 84% (p=0.01) in the children with CF. Time to Cmax (66±20 minutes) and elimination half-life (92±27 minutes) were not significantly different. No subjects were withdrawn from the study because of side effects. No adverse effects could be attributed to ibuprofen. Thus ibuprofen administration has no significant toxic effects, but Cmax will need to be monitored for effective dosing in patients with CF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barton AD
        • Ryder K
        • Lourenco RV
        • Dralle W
        • Weiss SG
        Inflammatory reaction and airway damage in cystic fibrosis.
        J Lab Clin Med. 1976; 88: 423-426
        • Davis PB
        Pathophysiology of pulmonary disease in cystic fibrosis.
        Semin Resp Med. 1985; 6: 261-270
        • Thomassen MJ
        • Demko CA
        • Doershuk CF
        Cystic fibrosis: a review of pulmonary infections and interventions.
        Pediatr Pulmonol. 1987; 3: 334-351
        • Auerbach HS
        • Williams M
        • Kirkpatrick JA
        • Colten HR
        Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.
        Lancet. 1985; 2: 686-688
        • Konstan MW
        • Vargo KM
        • Davis PB
        Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for antiinflammatory therapy in cystic fibrosis.
        Am Rev Respir Dis. 1990; 141: 186-192
        • deGroot R
        • Smith AL
        Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significances.
        Clin Pharmacokinet. 1987; 13: 228-253
        • Knoppert DC
        • Spino M
        • Beck R
        • Thiessen JJ
        • MacLeod SM
        Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease.
        Clin Pharmacol Ther. 1988; 44: 254-264
        • Knudson RJ
        • Lebowitz MD
        • Holdberg CJ
        • Burrows B
        Changes in the normal maximal expiratory flow-volume curve with growth and aging.
        Am Rev Respir Dis. 1983; 127: 725-734
        • Minkler PE
        • Hoppel CL
        Determination of ibuprofen in human plasma by high performance liquid chromatography.
        J Chromatogr. 1988; 428: 388-394
        • Barnhart ER
        Physicians' desk reference.
        in: Medical Economics Co Inc, Oradell, NJ1986: 1855
        • Maderazo EG
        • Breaux SP
        • Woronick CL
        Inhibition of human polymorphonuclear leukocyte cell responses by ibuprofen.
        J Pharm Sci. 1984; 73: 1403-1406
        • Flynn PJ
        • Becker WK
        • Vercellotti GM
        • et al.
        Ibuprofen inhibits granulocyte responses to inflammatory mediators: a proposed mechanism for reduction of experimental myocardial infarct size.
        Inflammation. 1984; 8: 33-44
        • Mills RFN
        • Adams SS
        • Cliffe EE
        • Dickinson W
        • Nicholson JS
        The metabolism of ibuprofen.
        Xenobiotica. 1973; 3: 589-598
        • Albert KS
        • Gernaat CM
        Pharmacokinetics of ibuprofen.
        Am J Med. 1984; 77: 40-46
        • Wechter WJ
        • Loughhead DG
        • Reischer RJ
        • VanGiessen GJ
        • Kaiser DG
        Enzymatic inversion at saturated carbon: nature and mechanism of the inversion of R(-)p-iso-butyl hydratropic acid.
        Biochem Biophys Res Comm. 1974; 61: 833-837
        • Leeder JS
        • Spino M
        • Isles AF
        • et al.
        Ceftazidime disposition in acute and stable cystic fibrosis.
        Clin Pharmacol Ther. 1984; 36: 355-362
        • Simila S
        • Kouvalainen K
        • Keinanen S
        Oral antipyretic therapy evaluation of ibuprofen.
        Scand J Rheumatol. 1976; 5: 81-83
        • Sheth UK
        • Gupta K
        • Paul T
        • Pispati PK
        Measurement of antipyretic activity of ibuprofen and paracetamol in children.
        J Clin Pharmacol. 1980; 20: 672-675
        • Keinanen-Kiukaanniema S
        • Simila S
        • Kouvalainen K
        Oral antipyretic therapy evaluation of the propionic acid derivatives ibuprofen, ketoprofen, fenoprofen and naproxen.
        Padiatr Padol. 1980; 15: 239-244
        • Kandoth PW
        • Joshi MK
        • Joshi VR
        • Satoskar RS
        Comparative evaluation of antipyretic activity of ibuprofen and aspirin in children with pyrexia of varied aetiology.
        J Int Med Res. 1984; 12: 292-297
        • Wilson G
        • Guerra AJ
        • Santos NT
        Comparative study of the antipyretic effect of ibuprofen (oral suspension) and paracetamol (suppositories) in paediatrics.
        J Int Med Res. 1984; 12: 250-254
        • Kotob A
        A comparative study of two dosage levels of ibuprofen syrup in children with pyrexia.
        J Int Med Res. 1985; 13: 122-126
        • Phadke MA
        • Paranjape PV
        • Joshi AS
        Ibuprofen in children with infective disorders: antipyretic efficacy.
        Br J Clin Pract. 1985; : 437-440
        • Amdekar YK
        • Desai RZ
        Antipyretic activity of ibuprofen and paracetamol in children with pyrexia.
        Br J Clin Pract. 1985; 39: 140-143
        • Walson PD
        • Galletta G
        • Braden NJ
        • Alexander L
        Ibuprofen, acetaminophen, and placebo treatment of febrile children.
        Clin Pharmacol Ther. 1989; 46: 9-17
        • Cunningham RJ
        • Brouhard BH
        • Berger M
        • Petrusick T
        • Travis LB
        Long-term use of propranolol, ibuprofen, and spironolactone in the management of Bartter's syndrome.
        Pediatrics. 1979; 63: 754-756
        • Lechacz G
        • Arbus GS
        • Balfe JW
        • Wolff ED
        • Robson L
        Effect of ibuprofen on growth in a child with Bartter syndrome.
        J Pediatr. 1979; 95: 319-320
        • Bettinelli A
        • Imbasciati E
        • Isimbaldi C
        • et al.
        Lack of hypertrophy of the juxtaglomerular apparatus (JGA) in Bartter's syndrome.
        International Journal of Pediatric Nephrology. 1980; 1: 177-182
        • Mennon ND
        • Whelton JJ
        • Ansell BM
        • Goldberg AAJ
        A comparative study of ibuprofen and aspirin in Still's disease (juvenile chronic polyarthritis).
        Curr Med Res Opin. 1974; 17: 17-18
        • Ansell BM
        Ibuprofen in the management of Still's disease.
        Practitioner. 1973; 211: 659-663
        • Brewer EJ
        Nonsteroidal antiinflammatory agents.
        Arthritis Rheum. 1977; 20 (suppl): 513-525
        • Mäkelä AL
        • Lempiäinen M
        • Yrjana T
        Ibuprofen in the treatment of juvenile rheumatoid arthritis: metabolism and concentrations in synovial fluid.
        Br J Clin Pract. 1980; 6 (suppl): 23-27
        • Mäkelä AL
        • Lempiäinen M
        • Ylijoki H
        Ibuprofen levels in serum and synovial fluid.
        Scand J Rheumatol. 1981; 39 ([Suppl]): 15-17
        • Morino F
        • Possati F
        • Santarelli P
        • et al.
        Use of ibuprofen in the control of rheumatic activity.
        Minerva Med. 1973; 64: 2475-2478
        • Durand Cl-H
        Complementary antiinflammatory treatment in general pediatrics.
        Gazz Med France. 1978; 85: 469-473
        • Lockwood GF
        • Albert KS
        • Gillespie WR
        • et al.
        Pharmacokinetics of ibuprofen in man. I. Free and total, area/dose relationships.
        Clin Pharmacol Ther. 1983; 34: 97-103
        • Juhl RP
        • Van Thiel DH
        • Dittert LW
        • Albert KS
        • Smith RB
        Ibuprofen and sulindac kinetics in alcoholic liver disease.
        Clin Pharmacol Ther. 1983; 34: 104-109
        • Albert KS
        • Gillespie WR
        • Wagner JG
        • Pau A
        • Lockwood GF
        Effects of age on the clinical pharmacokinetics of ibuprofen.
        Am J Med. 1984; 77: 47-50
        • Abernethy DR
        • Greenblatt DJ
        Ibuprofen disposition in obese individuals.
        Arthritis Rheum. 1985; 28: 1117-1121
        • Benvenuti V
        • Gambaro CV
        • Lodi F
        • et al.
        Pharmacokinetics of two new oral formulations of ibuprofen.
        Int J Clin Pharmacol Ther Toxicol. 1986; 249: 308-312
        • Small RE
        • Johnson SM
        • Willis HE
        Pharmacokinetic and taste evaluation of ibuprofen (Motrin) 800 mg tablets in extemporaneous solution.
        J Rheumatol. 1988; 15: 345-347